Cancer Pharmacologist and HTS Scientist

癌症药理学家和 HTS 科学家

• 批准号: 9766086
• 负责人: Joshua A. Bauer
• 金额: $ 11.58万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-19 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9766086
• 关键词: Applications Grants; Area; Biochemistry; Biological Assay; Biology; Cancer Biology; Cancer Center; Cancer Research Project; Chemicals; Collaborations; Comprehensive Cancer Center; Core Facility; Drug Screening; Educational workshop; Funding; Genomic approach; Genomics; Goals; Image; Institutes; Investigational Drugs; Knowledge; Libraries; Malignant Neoplasms; Manuscripts; Molecular Genetics; Molecular Probes; Pharmacology; Play; Research; Research Personnel; Role; Scientist; Services; Small Interfering RNA; Technology; Therapeutic; anticancer research; base; cancer cell; design; drug discovery; experience; functional genomics; high throughput screening; innovation; meetings; member; new therapeutic target; novel; programs; screening; skills; stem; success; symposium

Project Summary: The Vanderbilt-Ingram Cancer Center (VICC) is an NCI-designated Comprehensive Cancer Center with over 270 members focused on cancer-related research. The Vanderbilt Institute of Chemical Biology (VICB) High- Throughput Screening (HTS) core facility was established to provide screening-based services with investigators for molecular probe discovery. Dr. Joshua Bauer plays an integral role in the interface between the cancer research and chemical biology programs at Vanderbilt. He has a strong background in cancer biology, pharmacology, and biochemistry with functional genomic and drug screening experience. His main goal is to use chemical genomic approaches, including functional genomic screening and high-content imaging, to identify novel drug targets and to better understand the molecular and genetic mechanisms that underlie how cancer cells respond to therapeutics. To achieve this goal his cancer-related projects within the HTS facility are focused on three areas: 1) compound library screening and other HTS drug screening, 2) functional genomic (siRNA) library screening, and 3) high-content screening (HCS) and analysis. To date, Dr. Bauer has provided support and intellectual contributions to over 50 HTS projects, including collaborations with at least 19 Cancer Center members, including 13 that are NCI funded. The continued collaborations with cancer investigators has allowed him to develop innovative assays and novel screening projects that contribute to the success of the Vanderbilt HTS core and cancer research program. His vital role and success stems from his ability to collaborate, design and perform screens, and intellectually contribute to projects, grant proposals, and manuscripts. In addition, through participation in conferences, meetings and workshops Dr. Bauer strives to bring state-of-the-art technologies and ideas to the Vanderbilt HTS facility. The blend of his skills, expertise, and knowledge provide a unique role within Vanderbilt to mend cancer research, chemical biology, genomics, drug discovery, and translational drug investigation. Dr. Bauer's role as a Cancer Pharmacologist & HTS Scientist is completely indispensable to the cancer research program at Vanderbilt.

项目概要： 范德比尔特-英格拉姆癌症中心 (VICC) 是 NCI 指定的综合癌症中心，拥有超过 270 名成员专注于癌症相关研究。范德比尔特化学生物学研究所 (VICB) High- 建立通量筛选（HTS）核心设施，提供基于筛选的服务 分子探针发现的研究人员。 Joshua Bauer 博士在两者之间的联系中发挥着不可或缺的作用 范德比尔特大学的癌症研究和化学生物学项目。他在癌症方面有深厚的背景 生物学、药理学和生物化学，具有功能基因组和药物筛选经验。他的主要 目标是使用化学基因组方法，包括功能基因组筛选和高内涵 成像，以确定新的药物靶点并更好地了解分子和遗传机制 癌细胞如何对治疗作出反应的基础。为了实现这一目标，他在以下领域开展了与癌症相关的项目 HTS 设施专注于三个领域：1) 化合物库筛选和其他 HTS 药物筛选，2) 功能基因组（siRNA）文库筛选，以及3）高内涵筛选（HCS）和分析。迄今为止，博士。 Bauer 为 50 多个 HTS 项目提供了支持和智力贡献，包括与 至少 19 名癌症中心成员，其中 13 名是由 NCI 资助的。与以下机构的持续合作 癌症研究人员使他能够开发出创新的检测方法和新颖的筛查项目，这些项目有助于 范德比尔特 HTS 核心和癌症研究项目的成功。他的重要作用和成功源于 由于他的协作、设计和执行屏幕以及为项目做出智力贡献的能力，授予 提案和手稿。此外，通过参加大会、会议和研讨会，Dr. Bauer 致力于将最先进的技术和理念引入范德比尔特 HTS 工厂。他的融合 技能、专业知识和知识在范德比尔特大学内发挥着独特的作用，以改进癌症研究、化学研究 生物学、基因组学、药物发现和转化药物研究。鲍尔博士作为癌症患者的角色 药理学家和 HTS 科学家对于范德堡大学的癌症研究项目是完全不可或缺的。